Get the Stockscreener App
22.70
1.66%
0.4586
Harrow Inc stock is traded at $22.70, with a volume of 26,455.
It is up +1.66% in the last 24 hours and down -25.67% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans.
See More
Previous Close:
$22.24
Open:
$22.64
24h Volume:
26,455
Relative Volume:
0.08
Market Cap:
$792.07M
Revenue:
$154.15M
Net Income/Loss:
$-33.58M
P/E Ratio:
-23.64
EPS:
-0.96
Net Cash Flow:
$-20.74M
1W Performance:
-7.26%
1M Performance:
-25.67%
6M Performance:
-49.91%
1Y Performance:
+122.10%
1-Day Range:
$22.51
$23.44
1-Week Range:
$21.14
$24.00
52-Week Range:
$9.30
$59.23
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
102 WOODMONT BLVD, NASHVILLE, CA
Compare HROW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
22.76 | 792.07M | 154.15M | -33.58M | -20.74M | -0.96 |
|
ZTS
Zoetis Inc
|
160.08 | 71.40B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.01 | 47.36B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.19 | 46.03B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.36 | 18.86B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.25 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Harrow shares react modestly to FDA move - Nashville Post
Harrow shares react to FDA move - Nashville Post
Harrow Signs 5-Year Supply Deal for Triesence -March 11, 2025 at 08:36 am EDT - Marketscreener.com
Major Breakthrough: Harrow Ends TRIESENCE Shortage Crisis with 5-Year Manufacturing Deal - StockTitan
Harrow (HROW) to Release Quarterly Earnings on Monday - Defense World
Rhumbline Advisers Has $1.35 Million Position in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow, Inc. (NASDAQ:HROW) Shares Sold by New York State Common Retirement Fund - Defense World
Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025 - Business Wire
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update - GlobeNewswire Inc.
Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025 - Seeking Alpha
Implied Volatility Surging for Harrow (HROW) Stock Options - Nasdaq
Harrow (NASDAQ:HROW) shareholders have earned a 40% CAGR over the last five years - Yahoo Finance
Shareholders Should Be Pleased With Harrow, Inc.'s (NASDAQ:HROW) Price - Simply Wall St
Equitable Trust Co. Sells 14,670 Shares of Harrow, Inc. (NASDAQ:HROW) - MarketBeat
Harrow (NASDAQ:HROW) Stock Price Down 5.1%Here's What Happened - MarketBeat
Bleakley Financial Group LLC Buys 3,394 Shares of Harrow, Inc. (NASDAQ:HROW) - Defense World
What is HC Wainwright's Forecast for Harrow Q4 Earnings? - MarketBeat
HC Wainwright Comments on Harrow’s Q4 Earnings (NASDAQ:HROW) - Defense World
Harrow (NASDAQ:HROW) Coverage Initiated by Analysts at HC Wainwright - MarketBeat
H.C. Wainwright sets $57 target on Harrow Health stock - MSN
HC Wainwright & Co. Initiates Coverage of Harrow (HROW) with Buy Recommendation - MSN
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
15,448 Shares in Harrow, Inc. (NASDAQ:HROW) Acquired by Sonora Investment Management Group LLC - MarketBeat
Harrow (NASDAQ:HROW) Stock Price Down 4.6%Here's What Happened - MarketBeat
Fungal Keratitis Treatment Market Growth By 2031 | Harrow Inc., - openPR
SG Americas Securities LLC Acquires 18,815 Shares of Harrow, Inc. (NASDAQ:HROW) - MarketBeat
SG Americas Securities LLC Boosts Stake in Harrow, Inc. (NASDAQ:HROW) - Defense World
Commit To Buy Harrow At $23, Earn 18% Annualized Using Options - Nasdaq
Opaleye management sells $711,814 worth of Harrow shares - MSN
Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients - Business Wire
Harrow Launches 'Harrow Cares' Patient Support Program with Cencora Partnership - StockTitan
Harrow, Inc. (NASDAQ:HROW) Sees Board Member Resignation - Defense World
Opaleye Management Inc. Significantly Reduces Stake in Harrow Inc. - GuruFocus.com
Opaleye management sells $711,814 worth of Harrow shares By Investing.com - Investing.com South Africa
Harrow (NASDAQ:HROW) Trading Down 4.9%Time to Sell? - MarketBeat
Assenagon Asset Management S.A. Sells 79,071 Shares of Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow, Inc. (NASDAQ:HROW) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Brookstone Capital Management Invests $275,000 in Harrow, Inc. (NASDAQ:HROW) - Defense World
Brookstone Capital Management Purchases New Position in Harrow, Inc. (NASDAQ:HROW) - MarketBeat
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harrow Inc Stock (HROW) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Jan 22 '25 |
Sale |
35.59 |
20,000 |
711,814 |
155,000 |
| SAHAREK JOHN P. | CEO of ImprimisRx |
Sep 11 '24 |
Option Exercise |
7.37 |
90,000 |
663,300 |
344,803 |
| Opaleye Management Inc. | 10% Owner |
Apr 25 '24 |
Buy |
9.97 |
20,000 |
199,400 |
3,815,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 23 '24 |
Buy |
10.29 |
11,715 |
120,547 |
3,786,715 |
| Opaleye Management Inc. | 10% Owner |
Apr 24 '24 |
Buy |
10.15 |
8,285 |
84,093 |
3,795,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 19 '24 |
Buy |
10.56 |
29,400 |
310,390 |
3,775,000 |
| Opaleye Management Inc. | 10% Owner |
Mar 28 '24 |
Buy |
12.82 |
50,000 |
641,000 |
3,745,600 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Mar 22 '24 |
Buy |
11.59 |
9,000 |
104,310 |
2,137,525 |
| Opaleye Management Inc. | 10% Owner |
Mar 20 '24 |
Buy |
9.65 |
50,600 |
488,290 |
3,695,600 |
1.16%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):